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Background: Dendritic cell (DC)-based vaccines are cur-
rently being evaluated as a novel strategy for tumor vacci-
nation and immunotherapy. However, inducing long-term re-
gression in established tumor-implanted mice is difficult. 
Here, we show that deoxypohophyllotoxin (DPT) induces ma-
turation and activation of bone marrow-derived DCs via 
Toll-like receptor (TLR) 4 activation of MAPK and NF-κB. 
Methods: The phenotypic and functional maturation of 
DPT-treated DCs was assessed by flow cytometric analysis 
and cytokine production, respectively. DPT-treated DCs was 
also used for mixed leukocyte reaction to evaluate T cell-pri-
ming capacity and for tumor regression against melanoma. 
Results: DPT promoted the activation of CD8
＋ T cells and 
the Th1 immune response by inducing IL-12 production in 
DCs. In a B16F10 melanoma-implanted mouse model, we 
demonstrated that DPT-treated DCs (DPT-DCs) enhance 
immune priming and regression of an established tumor in 
vivo. Furthermore, migration of DPT-DCs to the draining 
lymph nodes was induced via CCR7 upregulation. Mice that 
received DPT-DCs displayed enhanced antitumor ther-
apeutic efficacy, which was associated with increased IFN-γ 
production and induction of cytotoxic T lymphocyte activity. 
Conclusion: These findings strongly suggest that the ad-
juvant effect of DPT in DC vaccination is associated with the 
polarization of T effector cells toward a Th1 phenotype and 
provides a potential therapeutic antitumor immunity. 
[Immune Network 2011;11(1):79-94]
INTRODUCTION
Recently, much research has focused on the biology of den-
dritic cells (DCs) and their possible clinical use as cellular ad-
juvants in treating patients with chronic tumors (1). The gen-
eration  of  an  optimal  immune  response  often  requires  the 
presence of CD4
＋ T helper cells as well as the expression 
of T cell-specific antigen on antigen-presenting cells (APCs) 
(2). As potent APCs, DCs possess immune sentinel properties 
which  enable,  the  induction  of  primary  immune  responses 
and initiation of T cell responses against microbial pathogens 
and tumors (3,4). Immature DCs capture and process exoge-
nous  agents  within  the  peripheral  tissues  in  which  they 
mature. Maturing DCs then migrate to the lymphoid organs 
where they stimulate naïve T cells by signaling through the 
major  histocompatibility  complex  (MHC)  and  co-stimulatory 
molecules (5). The maturation and differentiation of DCs re-
quire activation via phosphorylation of the mitogen-activated 
protein  kinases  (MAPK),  including  extracellular  signal  regu-
lated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38, 
as well as the transcription nuclear factor-κB (NF-κB) (6). 
DCs can also induce proliferation and generation of specific 
cytotoxic  T  lymphocyte  (CTL)  and  helper  T  cells  via  stim-
ulation  of  MHC  class  I  and  II  antigen  presentation  (7). 
Interestingly,  nonspecific  DC  stimulators,  including  bacterial 
outer membrane protein A (OmpA), can induce DC-mediated Deoxypodophyllotoxin Enhances DC-based Vaccine Efficacy
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MHC  class  I-primed  specific  CTL  responses.  OmpA-pulsed 
DCs also induce protective antitumor responses in vivo (8).
  In a tumor-bearing host, DCs present tumor peptides in as-
sociation with MHC class I and II molecules to stimulate spe-
cific CD4
＋ and CD8
＋ T cell responses (9). Moreover, apop-
totic tumor cells and tumor lysates (TP) provide DCs with a 
comprehensive  source  of  tumor  antigens  that  are  used  to 
cross-prime effector T cells (10-12). Formation of TP such as 
apoptotic tumor bodies in situ is generally thought to result 
from spontaneous tumor cell death or the activity of cytotoxic 
effector T cells (13,14). Recently, new approaches to tumor 
immunotherapy have focused on the enhancement of effector 
T  c e l l  r e s p o n s e s  b y  t h e  a c t i v a t i o n  o f  i n n a t e  i m m u n e  c e l l s  
through  their  receptors.  Among  others,  receptor  agonists 
(8,15) have been utilized to obtain such results. Pathogen rec-
ognition receptors such as the Toll-like receptors (TLR) have 
b e e n  t h e  p r i m a r y  t a r g e t s  o f  D C  a c t i v a t i o n  ( 1 6 , 1 7 ) .  I n d e e d ,  
they have already been used as immunotherapeutic agents in 
treating  cancer  patients (18). TLR agonists stimulate DC in-
flammatory cytokine production, including interleukin (IL)-12, 
thereby activating interferon (IFN)-γ-secreting Th1 cells, nat-
ural killer cells, and CD8
＋ CTL (19). Generally, most TLR ag-
onists promote Th1 cells (20). We and others have also dem-
onstrated  that  certain  pathogen-derived  molecules  that  en-
hance IL-12 and inhibit IL-10 production by DCs also promote 
the  induction  of  IFN-γ-secreting  T  cells  (21,22).
    Deoxypodophyllotoxin (DPT) is an active component and 
major lignan of the traditional plant Anthriscus sylvestris. DPT 
also known exhibits exert antitumor (23) and antiviral activ-
ities (24). Until now, the cellular targets of DPT in the im-
mune system have remained unknown. We have attempted 
to characterize the effects of DPT on the maturation and func-
tional properties of murine bone marrow (BM)-derived DCs. 
Additionally,  their  functional  effects  on  DC-mediated  T  cell 
immunity  and  antitumor  activity  were  investigated.
MATERIALS AND METHODS
Animals and cell line
Male 6∼8 week-old C57BL/6 (H-2K
b and I-A
b) and BALB/c 
(H-2K
d a n d  I - A
d)  mice  were  purchased  from  the  Korean 
Institute of Chemistry Technology (Daejeon, Korea). C.Cg-Tg 
(DO11.10,  H-2
d,  OT-II)  mice  carrying  the  MHC  class  II-re-
stricted  rearranged  T  cell  and  C57BL/6-Tg  (TcraTcrb,  H-2
b, 
OT-1) mice containing transgenic inserts for mouse Tcra-V2 
and  Tcrb-V5  genes,  which  encode  recognition  of  OVA257-267 
were  purchased  from  the  Jackson  Laboratory  (Bar  Harbor, 
ME). The mice were housed in a pathogen-free environment 
within our animal facility for at least 1 week before use and 
were used in accordance with the institutional guidelines for 
animal care. C57BL/6-derived tumor cell lines, F10 sublines 
of B16 melanoma, were obtained from the Korean Cell Line 
Bank (Seoul, Korea). B16F10 melanoma cells were cultured 
in  Dulbecco’s  modified  Eagle’s  medium  supplemented  with 
2 mM L-glutamine, 1,000 U/ml Penicillin, 50μg/ml strepto-
mycin, and 10% fetal bovine serum (FBS). Cells were main-
tained at 37
oC in 5% CO2. Confluent growth was obtained in 
100 mm diameter dishes and cells were routinely passaged 
every  2  days.
Isolation of deoxypodophyllotoxin
DPT was isolated from the dried roots of Anthriscus sylvestris 
a s  d e s c r i b e d  b y  J i n  e t  a l .  ( 2 5 ) .  B r i e f l y ,  w h o l e  c o m p o u n d s  
from  the  roots  of  Anthriscus  sylvestris  were  extracting  by 
e t h a n o l  e x t r a c t i o n  a n d  t a r g e t  c o m p o u n d  ( D P T ,  m p  1 6 6 ∼
167
oC, [α]D
23−110
o (c=1.0, CHCl3)) was extracted by HPLC. 
The  purity  of  this  compound  was  above  99.5%  based  on 
HPLC analysis. The DPT used in this study ran as a single 
spot on thin layer chromatography and a solution was pre-
pared by dissolving pure DPT in dimethyl sulfoxide (DMSO) 
diluted with DMEM media. DPT was dissolved in DMSO for 
further  study.  The  final  concentrations  of  DMSO  were  ad-
justed  to  0.1%  (v/v)  in  the  culture  media.
Reagents and Antibodies
Recombinant mouse (rm) GM-CSF and rmIL-4 were purchased 
from R&D Systems. Dextran- FITC (molecular mass 40,000), 
and LPS (from Escherichia coli 055:B5) were obtained from 
Sigma-Aldrich. An endotoxin filter (END-X) and endotoxin re-
moval resin (END-X B15) were acquired from Associates of 
C a p e  C o d .  C y t o k i n e  E L I S A  k i t s  f o r  m u r i n e  I L - 1 2  p 7 0 ,  I L - 2 ,  
IL-4, IL-10, and IFN-γ were purchased from BD PharMingen. 
FITC- or PE-conjugated monoclonal antibodies (mAbs) used 
for flow cytometry to detect CD11c (HL3), CD80 (16-10A1), 
CD86  (GL1),  CD40  (1C10),  IA
b  β-chain  (AF-120.1),  H2K
b 
(AF6-88.5),  CD4  (L3T4),  IL-12  p40/p70  (C15.6),  and  IL-10 
(JESS-16E3), as well as isotype-matched control mAbs and bi-
otinylated anti- CD11c (N418) mAb, were purchased from BD 
PharMingen. To detect protein levels by western blotting, an-
ti-phospho-ERK,  anti-ERK,  anti-phospho-p38,  and  anti-p38 
were purchased from Cell Signaling. Anti-p65 Ab was from 
Abcam.Deoxypodophyllotoxin Enhances DC-based Vaccine Efficacy
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Generation and culture of DCs
DCs were generated from murine whole bone marrow (BM) 
cells. Briefly, BM was flushed from the tibiae and femurs of 
C57BL/6 and BALB/c mice and depleted red cells with ammo-
nium chloride. The cells were plated in 6-well culture plates 
(10
6 cells/ml, 3 ml/well) and cultured at 37
oC in 5% CO2 and 
OptiMEM  (Invitrogen  Life  Technologies)  supplemented  with 
10% heat-inactivated fetal bovine serum (FBS), 2 mM L-gluta-
mine, 100 U/ml penicillin, 100μg/ml streptomycin, 5×10
−5 
M  β-mercaptoethanol,  10  mM  HEPES  (pH  7.4),  20  ng/ml 
rmGM-CSF,  and  rmIL-4.  On  day  3  of  culture,  floating  cells 
were gently removed and fresh medium was added. On day 
6 or 7, nonadherent cells and loosely adherent proliferating 
DC aggregates were harvested for analysis or stimulation, or 
in  some  experiments,  replated  into  60  mm  dishes  (10
6 
cells/ml,  5  ml/dish).  On  day  6,  80%  or  more  of  the  non-
adherent  cells  expressed  CD11c.  To  obtain  highly  purified 
populations  for  subsequent  analyses,  the  DCs  were  labeled 
with bead-conjugated anti-CD11c mAb (Miltenyi Biotec) fol-
lowed by positive selection on paramagnetic columns (LS col-
umns,  Miltenyi  Biotec)  according  to  the  manufacturer’s  in-
structions. The purity of the selected cell fraction was ＞95%.
Stimulation of DCs by DPT and B16-TP
DPT  and  B16F10-tumor  lysates  (B16-TP)  were  dissolved  in 
culture media and were added to cultures of isolated DCs in 
six-well plates (10
6 cells/ml, 2 ml/well). For the analysis of 
apoptosis, DCs were stimulated with DPT in media or media 
alone, and apoptosis was analyzed over time by staining of 
surface-exposed phosphatidylserine with FITC-annexin V and 
propidium  iodine  (BD  PharMingen  kit).
Flow cytometry
On day  6, BM-DCs were harvested, washed with PBS, and 
resuspended  in  fluorescence  activated  cell  sorter  (FACS) 
washing buffer (2% FBS and 0.1% sodium azide in PBS). The 
cells were blocked with 10% (v/v) normal goat serum for 15 
min at 4
oC, and stained with phycoerythrin (PE)-conjugated 
anti- H-2K
b [major histocompatibility complex (MHC) class I], 
anti-I-A
b (MHC class II), anti-CD40, anti-TLR4, anti-CD80, and 
anti-CD86  with  fluorescein  isothiocyanate  (FITC)-conjugated 
anti-CD11c (PharMingen, San Diego, CA) for 30 min at 4
oC. 
The stained cells were analyzed using a FACSCalibur flow cy-
tometer  (Becton  Dickinson,  San  Jose,  CA).
Quantitation of antigen uptake
In brief, 2×10
5 cells were equilibrated at 37
oC or 4
oC for 45 
min and pulsed with fluorescein-conjugated dextran (40,000 
molecular  mass,  Sigma-Aldrich)  at  a  concentration  of  1 
mg/ml. Cold staining buffer was added to stop the reaction. 
T h e  c e l l s  w e r e  w a s h e d  3  t i m e s  a n d  s t a i n e d  w i t h  P E - c o n -
jugated  anti-CD11c  Abs,  and  then  analyzed  with  the 
FACSCalibur. Nonspecific binding of dextran to DCs was de-
termined by incubation of DCs with FITC-conjugated dextran 
at  4
oC  to  obtain  a  background  level.  The  medium  used  in 
the  cultures  with  DPT  stimulation  was  supplemented  with 
GM-CSF,  which  is  required  for  DCs  to  capture  antigen.
Cytokine assays
Cells were blocked with 10% (v/v) normal goat serum for 15 
min at 4
oC, and stained with FITC-conjugated CD11c
＋ anti-
body for 30 min at 4
oC. Cells stained with the appropriate 
isotype-matched Ig were used as negative controls. The cells 
were fixed and permeabilized with the Cytofix/Cytoperm kit 
(PharMingen). Intracellular IL-12p40/p70 and IL-10 were de-
tected  with  fluorescein  R-PE-conjugated  antibodies  (Phar-
Mingen)  in  permeation  buffer.  The  cells  were  analyzed  on 
a  FACSCalibur  flow  cytometer  with  the  CellQuest  program. 
The presence of murine IL-12p70, IL-2, IL-4, and IFN-γ was 
measured  using  an  ELISA  kit  (R&D  Systems).
T cell proliferation and cytokine production by syn-
geneic MLR
Responder CD8
＋ T cells recognizing OVA257-264 were isolated 
from the spleens of C57BL/6-Tg (TcraTcrb, H-2
b, OT-1) mice 
via  a  MACS  column  (Miltenyi  Biotec,  Gladbach,  Germany). 
CD8
＋ T  c e l l s  w e r e  l a b e l e d  w i t h  b e a d - c o n j u g a t e d  a n t i - C D 8  
mAb (Miltenyi Biotec) followed by positive selection on para-
magnetic columns. The lymphocyte population (98% of CD8
＋ 
T cells) was then washed twice in PBS and labeled with car-
boxyfluorescein succinimidyl ester (CFSE), as previously de-
scribed (26). Stimulator DCs (1×10
4) derived from C57BL/6 
mice were exposed to DPT (100 nM) or LPS (200 ng) for 24 
h, washed thoroughly, and co-cultured with 1×10
5 CFSE-la-
beled T cells in 96-well U-bottom plates for another 3 days. 
The cells were harvested and washed in PBS. CFSE dilution 
was assessed by flow cytometry. A negative control (CD8
＋ 
T  cells  in  media  alone),  a  specific  antigen  control  (1μM 
OVA257-264) and a positive control (CD8
＋ T cells in 200 ng/ml 
LPS) were created for each experiment. CD4
＋ splenic T cells 
(2×10
6/ml)  form  DO11.10  mice  were  co-cultured  with Deoxypodophyllotoxin Enhances DC-based Vaccine Efficacy
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(2×10
5/ m l )  B A L B / c  D C s  i n  9 6 - w e l l  U - b o t t o m  p l a t e s  f o r  2 4 
h  in  the  presence  or  absence  of  100  nM  DPT.  To  all  ex-
perimental groups except the specific antigen control, 1μM 
OVA323-339 peptide was added. Cytokine profiles, e.g., IFN-γ 
(Th1)  and  IL-4  (Th2)  were  analyzed  by  flow  cytometry. 
Supernatants from these cultures were collected after 2 days 
and  analyzed  by  ELISA.
Nuclear and cytoplasmic extracts and western blot
The  cells  were  exposed  to  LPS  (200  ng)  or  100  nM  DPT. 
Following 15, 30, and 45 min incubation at 37
oC, cells were 
washed twice with cold PBS and lysed with modified RIPA 
buffer (1.0% NP-40, 1.0% sodium deoxycholate, 150 nM NaCl, 
10 mM Tris-HCl [pH 7.5], 5.0 mM sodium pyrophosphate, 1.0 
mM NaVO4, 5.0 mM NaF, 10 mM/ml leupeptin, and 0.1 mM 
phenylmethylsulfonyl  fluoride)  for  15  min  at  4
oC.  Lysates 
were cleared by centrifuging at 14,000×g for 20 min at 4
oC. 
The protein content of cell lysates was determined using the 
Micro  BCA  assay  kit  (Pierce,  Rockford,  IL).  Equivalent 
amounts  of  proteins  were  separated  by  10%  or  12%  SDS- 
PAGE  and  analyzed  by  western  blotting  using  anti-phos-
pho-ERK1/2 (p-ERK, Cell Signaling, MA) or anti-phospho-p38 
(p-p38,  Cell  Signaling,  MA)  MAPK  mAb  for  3  h.  Following 
3 washes with Tris buffered saline with Tween (TBST), mem-
branes  were  incubated  with  secondary  horse  radish  perox-
idase (HRP)-conjugated anti-mouse IgG for 2 h. After wash-
ing,  the  blots  were  developed  using  the  enhanced  chem-
iluminescence (27) system (Amersham). DC nuclear extracts 
were  prepared  using  NE-PER  nuclear  and  cytoplasmic  ex-
traction  reagents  (Pierce,  Rockford,  IL).  NF-κB  p-p65  sub-
units in the nuclear extracts were detected by western blot 
analysis  with  an  anti-  NF-κB  p-p65  subunit  Ab  (p-p65, 
Abcam,  UK).
Evaluation of gene expression by real-time PCR
TLR PCR primers included the following: TLR1, 2, 4, 5, and 
6.  Quantitative  amounts  of  each  gene  were  standardized 
against the GAPDH housekeeping gene. Real-time PCR was 
performed  using  a  BioRad  MiniOpticon  System  (BioRad 
Laboratories,  Ltd)  with  SYBR  green.  Reactions  were  per-
formed in a total volume of 20μl-including 10μl 2x SYBR 
Green  PCR  Master  Mix  (Applied  Biosystems),  1μl  of  each 
primer at 10μM concentration and 1μl of the reverse-tran-
scribed cDNA template. The cycling protocols was as follows: 
denaturation  (95
oC  f o r  1 0  m i n ) ,  a m p l i f i c a t i o n  r e p e a t e d  4 0  
times (95
oC for 30 s, 52
oC for 30 s, 72
oC for 30 s, and acquis-
ition temperature for 15 s). For each sample, ddCt (crossing 
point) values were calculated as the Ct of the target gene mi-
nus the Ct of the GAPDH gene. Gene expression was derived 
according to the equation 2
−ddCt; changes in gene expression 
were  expressed  in  relation  to  the  basal  level.
Migration of DCs in vivo
CD11c bead-purified DCs were labeled with CFSE, according 
t o  t h e  m a n u f a c t u r e r ’s  instructions.  Thereafter,  1×10
6 u n -
treated, B16-TP-DCs, DTP-DCs were injected subcutaneously 
into  one  hind  footpad  of  normal  syngeneic  recipients 
(C57BL/6). Popliteal lymph nodes were removed 24 h after 
DCs injection, the optimal time described by Abe et al. (28). 
Ipsilateral inguinal LN were also removed and served as neg-
ative controls. LN cells were analyzed by flow cytometry. The 
number of DCs migrating to draining (D) LN was determined 
as follows; percent green fluorescent cells in DLN×total num-
b e r  o f  c e l l s  r e c o v e r e d  f r o m  D L N / n u m b e r  o f  D C s  i n j e c t e d .
Tumor lysate pulsing
B16-TP were prepared as previously described (14). B16F10 
melanoma cells were resuspended in extraction buffer con-
taining 0.01 M/L Tris-HCl (pH 7.2) and 0.2 mM/L CaCl2 (10 
ml per gram of tumor cells) and homogenized for 3 min on 
ice  using  a  Silverson  homogenizer.  Cell  extracts  were  har-
vested by centrifugation at 1,000×g for 5 min to remove cel-
lular debris. For tumor lysate pulsing 5 to 10×10
6 DCs were 
pulsed with B16-TP at a ratio 3：1 (three tumor cell lysates 
per dendritic cells) in OptiMEM (Invitrogen Life Technologies) 
s u p p l e m e n t e d  w i t h  1 0 %  F B S ,  2 0  n g / m l  r m G M - C S F ,  a n d  
rmIL-4  at  37
oC  overnight.
Treatment of established tumors
C57BL/6  mice  (ten  each  group)  were  subcutaneously.  in-
jected  in  their  right  flank  with  1×10
6  viable  B16F10  tumor 
cells.  Mice  were  monitored  daily  for  tumor  progression  or 
regression. Mice were subcutaneously vaccinated with 1×10
6 
D C s  w i t h  m e d i u m ,  B 1 6 - T P  p u l s i n g ,  a n d  D P T  t r e a t e d  D C s ,  
respectively. The tumor length (L) and width (W) was meas-
ured  at  different  time  points  and  tumor  volume  was  de-
termined  by  L×W
2/2.
Cytotoxic assay of CTL
Splenic  lymphocytes  were  isolated  form  killed  tumor  im-
planted mice 5 days after the last injection in each DC vacci-
nation  groups.  The  lymphocytes  were  co-cultured  with  in-Deoxypodophyllotoxin Enhances DC-based Vaccine Efficacy
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Figure 1. DPT is not cytotoxic to DCs. Chemical structures of deoxypodophyllotoxin (DPT) (A) On day 6, the cells were cultured under standard 
conditions for another 24 h in the presence of 1 nM to 1,000 nM DPT and harvested. The cells were gated on CD11c
＋ cells, and analyzed 
by 2-color flow cytometry using AnnexinV/PI staining kit [H2O2 (200μM positive control)] (B) This result is representative of 3 experiments 
that gave similar results.
activated B16F10 cells (treated by 100μg/ml) mitomycin for 
30  min  for  7  day  in  the  presence  of  recombinant  IL-2  (20 
U/ml) and then collected as CTL effector cells. CTL activity 
was determined by lactate dehydrogenase (LDH) release as-
say with a CytoTox96 Non-Radioactive Cytotoxicity Assay Kit 
(Promega). The target cells (B16F10) were washed 3 times 
with RPMI-1640 containing 10% FBS to remove LDH derived 
from lysed cells. The amount of released LDH was detected 
in  an  ELISA  reader  at  a  wavelength  of  490  nm.
Cytokine release assay
Non-adherent  splenocytes  derived  from  tumor  implanted 
mice 7 days after their final injection were washed with twice 
with  PBS.  The  splenic  lymphocytes  (2×10
6 c e l l s / m l )  w e r e  
stimulated  with  inactivated  B16F10  cells  at  a  10：1  ratio. 
Supernatants  were  collected  for  IL-2  and  IFN-γ  assays. 
Cytokines were quantified with an ELISA kit (R&D systems).
Statistical analysis
Results are presented as the means±standard deviation (SD). 
Data  were  analyzed  by  one-way  analysis  of  variance 
(ANOVA) followed by Duncan’s post hoc test using SPSS ver-
sion  11.0  (SPSS,  Inc.,  Chicago,  IL).  Throughout  the  figures 
and legends the following terminology is used to denote stat-
istical  significance:  **p＜0.01,  *p＜0.05.
RESULTS
Purification and characterization of DPT
DPT was purified from the root of Anthriscus sylvestris (Fig. 
1A). To assess its cytotoxicity in DCs, cells were treated with 
various DPT concentrations for 24 h. No marked differences 
i n  t h e  p e r c e n t a g e  o f  d e a d  c e l l s ,  a s  d e f i n e d  b y  C D 1 1 c  a n d  
Annexin  V/propidium  iodide  staining  (Fig.  1B),  was  ob-
served. However, we found weak dead cells percentage of 
dendritic cells over 200 nM of DPT treatment (less than 6% 
of  dead  cells).  Therefore,  we  decided  to  use  the  concen-
tration  at  less  than  100  nM  in  the  following  experiments.Deoxypodophyllotoxin Enhances DC-based Vaccine Efficacy
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Figure 2. DPT induces the expression of MHC class I and II, co-stimulatory molecules in a dose-dependent manners and decreased endocytic 
capacity in DCs. The DCs were cultured under standard conditions for 24 h in the presence of 1 to 100 nM DPT or 200 ng/ml LPS, harvested,
and analyzed by 2-color cytometry. The cells were first gated on CD11c
＋. Medium represents the untreated control and LPS represents the
positive control. DPT was added to the DCs for 24 h at concentrations of 1 to 100 nM (A) FITC-dextran uptake was analyzed by CD11c
＋
-PE/dextran-FITC-positive cells using flow cytometry. DCs (1×10
5 cells) were treated with DPT (100 nM) or LPS (200 ng/ml) for 24 h (B) Endocytic
activity of the control was determined after incubation at 4
oC. The numbers represent the percentage of FITC-dextran/CD11c
＋-PE double positive
cells. Histogram of Fig. 2B was shown (thick line; endocytic activity control at 4
oC, thin line: endocytic activity at 37
oC).
DPT induced the maturation of murine bone marrow- 
derived DCs
Initially, we sought to determine the effects of DPT on the 
maturation  of  sentinel  DCs  into  effector  DCs.  Bone  mar-
row-derived DCs were cultured for six days in medium sup-
plemented  with  20  ng/ml  each  of  granulocyte  macrophage 
colony-stimulating factor and IL-4. Different concentrations of 
DPT were added on day 6 and lipopolysaccharide (LPS) was 
used as a positive control. We investigated the effects of a 
range of DPT concentrations on DC maturation. Bone mar-
row-derived DCs were cultured for 24 h in the presence of 
0 to 100 nM DPT as described in Materials and Methods. The 
DC  populations  were  subsequently  analyzed  by  flow  cy-
tometry for expression of cell surface molecules involved in 
CTL  activation,  namely  the  B 7  f a m i l y  m a r k e r s  C D 8 0  a n d  
CD86, as well as MHC class I and II. Expression of these mol-
ecules on DCs increased in response to DPT treatment in a 
dose-dependent manner (Fig. 2A) and was similar to the re-Deoxypodophyllotoxin Enhances DC-based Vaccine Efficacy
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Figure 3. DPT induces the production of IL-12 through MAPK and NF-κB in DCs. DCs were generated by stimulating immature DCs with 
1 to 100 nM DPT or 200 ng/ml LPS (Positive control) for 24 h. After 24 h, the production of IL-12 and IL-10 was measured by flow cytometry
(A) Analysis of IL-12 p70 and IL-10 production by magnetic bead-purified DC (1×10
6 cells) using ELISA. **p＜0.01 for a comparison with medium
control (B) For MAPK and NF-κB activation analysis, DCs were pretreated with 100 nM DPT for 15, 30, and 45 min. The cell lysates were
prepared and blotted with anti-phosho ERK1/2 and anti-phosho-p38 Ab. The nuclear extracts were blotted with anti-p65 Ab. The results are 
derived from 1 experiment with triplicate samples (C) DCs were pretreated with medium alone, LPS (positive control, 200 ng/ml), and DPT 
(100 nM) for 6 h. After 6 h, RNA was isolated and evaluated for TLR gene expression by quantitative real-time PCR. **p＜0.01 for a comparison
with medium control (D). The expression level of TLR4 after 24 h by stimulation was measured by flow cytometry (E).
sponse to LPS treatment. In contrast, untreated DCs retained 
an immature phenotype. Immature DCs are efficient at cap-
turing  antigen  and  undergoing  endocytosis.  To  investigate 
whether DPT modulates the ability of DCs to perform andti-
gen endocytosis, dextran uptake was analyzed. Uptake was 
significantly lower in DPT- and LPS-treated DCs than in un-
treated immature DCs (Fig. 2B), indicating a decrease in anti-
gen  endocytosis  by  the  treated  cells.
DPT induces IL-12 secretion but not IL-10 production 
during DC maturation
Previous reports have suggested that DCs, as well as macro-
phages  and  monocytes,  function  as  sources  of  pro-in-
flammatory molecules (29). In addition, CD4
＋ T lymphocytes 
differentiate  into  varying  subsets  of  effector  cells,  including 
Th1 and Th2 cells. The potent factors driving Th1 and Th2 
differentiation are IL-12, which is secreted by DCs, and IL-4, 
which is secreted by T cells (30). We assessed the ability of Deoxypodophyllotoxin Enhances DC-based Vaccine Efficacy
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Figure 3. Continued.
DCs to produce pro-inflammatory cytokines such as IL-12 and 
IL-10. IL-12 secretion is a marker for DCs activity and matura-
tion and can be used to promote Th1 cells and induce IFN-γ 
production. IL-12 is also a maturation factor for CTL (31). The 
secretion of bioactive IL-12 p70 requires the coordinated ex-
pression of two subunits, p35 and p40, which are encoded 
by two independently regulation (32). We analyzed the pro-
duction of both intracellular IL-12 p40/p70 and bioactive IL-12 
p70 in DCs treated with increasing concentrations of DPT. As 
shown in Fig. 3A, DCs stimulated with 100nM DPT induced 
large amounts of IL-12 p40/p70 (29.6±1.6%), whereas IL-10 
was  only  marginally  detected  above  control  levels  (3.8± 
0.1%). When supernatants were analyzed by ELISA, IL-10 was 
not detected above baseline levels 24 h after stimulation with 
100 nM DPT. In contrast, ELISA analysis revealed high levels 
of IL-12 p70 upon stimulation of DCs with DPT (248.1±12.07 
pg/ml with DPT versus 96.8±12.8 pg/ml with medium alone) 
for 24 h (Fig. 3B). These results indicate that DPT exposure 
induced the DCs to generate large amounts of IL-12 p70 and, 
by implication, other pro-inflammatory cytokines. These find-
ings also suggest that DPT can induce functional maturation 
of DCs, which can lead to a DC-mediated Th1 immune re-
sponse  and/or  CTL  activity.
DPT-induced DC maturation involves TLR4, MAPK, 
and NF-κB activation
MAPK  activation  is  important  for  DC  maturation  (33).  LPS 
stimulation affects the activation of these signaling pathways 
in DCs. Fig. 3C shows LPS activation via phosphorylation of 
p38 and ERK1/2. In order to characterize the effects of DPT 
on  the  phosphorylation  of  these  MAPK  in  DCs,  we  treated 
immature DCs with 100 nM DPT. We observed a marked in-
crease in phosphorylation of each kinase. Total ERK1/2 pro-
tein was expressed constitutively (Fig. 3C). Studies have also 
reported other signaling pathways involved in DC maturation, 
including  the  NF-κB  pathway  (21,34).  To  characterize  the Deoxypodophyllotoxin Enhances DC-based Vaccine Efficacy
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role  of  NF-κB  translocation  more  precisely,  we  stimulated 
immature DCs with DPT, then prepared nuclear extracts and 
evaluated the presence of the NF-κB p65 subunit by western 
blot. As before, LPS treatment was used as a positive control, 
and found to enhance nuclear translocation of p65 within 60 
min of exposure. Similarly, pretreatment of DCs with 100 nM 
DPT  resulted  in  p65  nuclear  translocation  (Fig.  3C).  One 
group of membrane receptors shown to play a key role in 
the innate immune system and DC activation are the Toll-like 
receptors (TLR) (35). TLRs are responsible for activating many 
signaling molecules, including MAPK, NF-κB, and IFN regu-
l a t o r y  f a c t o r s  ( 3 6 , 3 7 ) .  F o r  e x a m p l e ,  T L R  s i g n a l i n g  i n  D C s  
c a u s e s  u p r e g u l a t i o n  o f  C D 8 0 ,  C D 8 6 ,  a n d  C D 4 0 ,  a s  w e l l  a s  
induction of IL-12 and IFN-γ, all of which act to drive Th1 
and CD8
＋ T cell activation. Therefore, we proceeded to de-
termine  whether  DPT  led  to  TLR  activation  during  DC 
maturation. As seen in Fig. 3D and E, we performed quantita-
tive real-time PCR and antibody staining of TLR4 after stim-
ulation by LPS and DPT. Pretreatment of cells with DPT in-
c r e a s e d  T L R 4  e x p r e s s i o n  1 . 6 4 - f o l d ,  w h e r e a s  o t h e r  T L R  r e -
ceptors  remained  at  near  undetectable  levels.
DPT-treated DCs enhance CD8
＋ T cell proliferation 
and differentiation to a Th1 phenotype
Increased expression of B7 family members along with MHC 
I and II in DCs promotes their interaction with and activation 
of  T  cells.  We  investigated  whether  DPT-treated  DCs  stim-
ulate proliferation of CD8
＋ T cells in a syngeneic mixed lym-
phocyte  reaction.  DPT-treated  DCs  derived  from  wild-type 
mice stimulated proliferation of T cells derived from OT-1 Tg 
mice. As shown in Fig. 4A, DCs treated with DPT or LPS ex-
hibited  significantly  greater  proliferation  rates  than  those  of 
the control cells. In fact, the stimulatory effect of DPT was 
similar to activation by LPS. To determine whether DPT ex-
erts any effect on CD8
＋ T cell activation, we treated DCs with 
DPT for 24 h. ELISA analysis of culture supernatants revealed 
that the amount of IL-2 produced by CD8
＋ T cells increased 
following DPT treatment (Fig. 4D). Because DCs are also ca-
pable of inducing the polarization of naïve T cells, we eval-
uated the ability of DPT-activated DCs to induce a Th1 phe-
notype from naïve CD4
＋ T cells. CD4
＋ splenic T cells from 
DO11.10 Tg mice were co-cultured with DPT-treated DCs de-
rived from wild-type mice in the presence of 1μM OVA323-339 
peptide. ELISA analysis showed that IFN-γ, but not IL-4, se-
cretion increased in response to DPT (Fig. 4B and C). These 
results  suggest  that  DPT  directs  CD4
＋ T  c e l l  d i f f e r e n t i a t i o n 
towards  a  Th1  phenotype  by  inducing  IL-12  production.
DPT induces DCs migration by increasing CCR7 ex-
pression
Following effector stimulation, DCs undergo functional matu-
ration, enter the afferent lymph system, and interact with na-
ïv e  T  c e l l s  i n  o r d e r  t o  p r i m e  t h e  T  c e l l  r e s p o n s e  ( 3 8 ) .  
Maturation and activation result in changes in the migratory 
behavior of DCs as a result of altered expression of chemo-
taxis-related molecules such as CCR7, which is upregulated, 
and CCR3, which is downregulated (39). We investigated the 
expression of these chemokine receptors in DPT-treated DCs. 
LPS was used as a positive control as previous studies have 
shown  that  LPS  can  induce  DC  maturation  via  CCR7  upre-
gulation. DCs were treated with DPT for 12 h, after which 
quantitative real-time PCR was performed to assess CCR3 and 
CCR7  expression.  CCR7  mRNA  levels  were  upregulated 
whereas CCR3 mRNA was downregulated in DPT-treated DCs 
(Fig. 5A and B). We next investigated the ability of B16 tu-
mor lysate-pulsed (B16-TP)-DCs and DPT-treated DCs to mi-
grate  to  draining  lymph  nodes  (DLN)  after  subcutaneous 
injection.  Both  were  labeled  with  CFSE  immediately  after 
overnight culture in the presence of B16-TP or DPT, followed 
by subcutaneous injection into the hind footpads of syngeneic 
C57BL/6 mice. After 24 h, popliteal DLN were removed and 
cells were analyzed by flow cytometry to determine the per-
centage  of  CFSE  positive  cells  (Fig.  5C).  Interestingly,  sig-
nificantly more DPT-treated DCs migrated to the DLNs than 
untreated  DCs  and  B16-TP-DCs.  These  results  indicate  that 
DPT-treated DCs induce migratory effects in vitro and in vivo.
DPT-treated DCs enhance the therapeutic efficacy 
of DC-based immunization against tumors
We first examined whether DPT-treated DCs could enhance 
immune  priming  in  mice implanted  with  an  established  tu-
mor, B16F10 melanoma. As shown in Fig. 6A, mice that re-
ceived B16-TP-DCs alone showed 40% protection from tumor 
challenge  and  survived  over  80  days.  Immunization  with 
DPT-treated DCs resulted in additional protection from tumor 
challenge;  80%  of  these  mice  survived  over  time.  To  de-
termine  the  therapeutic  potential  of  immunization  with 
D P T - D C s ,  t u m o r  r e j e c t i o n  w a s  a s s e s s e d  i n  m i c e  i m p l a n t e d  
with an established B16F10 melanoma. After 28 days, mice 
that received B16-TP-DCs showed a partial reduction in tumor 
size (mean=1,325 mm
3±372; p＜0.001) compared to mice re-
ceiving  HBSS  (mean=2,575  mm
3±733)  (Fig.  6B,  28  days). Deoxypodophyllotoxin Enhances DC-based Vaccine Efficacy
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Figure 4. DPT-treated DCs induced the differentiation of T cells to a 
Th1 response. CD8
＋ T cell proliferation was analyzed by flow 
cytometry and presented as the percentage of dividing cells. A 
negative control (CD8
＋ T cells in untreated DC alone), a specific Ag 
control (1μM OVA257-264) and a positive control (CD8
＋ T cells in 200 
ng/ml LPS) were created for each experiment (A) To analyze cytokine 
production, CD4
＋ T cells of DO11.10 Tg mice and CD8
＋ T cells of 
OT-1 Tg mice were co-cultured in medium, LPS, or DPT-treated DC 
with or without OVA at 1：10 DC/T cell ratio for 48 h. After 48 h 
of expansion, IFN-γ (B), IL-4 (C) and IL-2 (D) were measured by ELISA 
in culture supernatants. Data are the mean±S.D. of 4 independent 
experiments. **p＜0.01 for a comparison with medium control. Deoxypodophyllotoxin Enhances DC-based Vaccine Efficacy
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Figure 5. DPT treatment of DCs increased expression of CCR7 and 
migration to DLN. DCs were treated with medium or DPT (100 nM) 
for 12 h. After 12 h, RNA was isolated and evaluated for CCR 7 (A) 
and CCR 3 (B) gene expression by quantitative real-time PCR. Fold 
differences compared with medium alone are depicted after normali-
zation with the housekeeping gene. **p＜0.01 for a comparison with 
medium control. Fluorescence-activated cell sorter analysis was 
performed on cells from DLN isolated 24 h after subcutaneous 
injection of DCs alone, B16-TP-DCs, and DPT treated DCs with 1×10
6
cells, bead-purified, CFSE-labeled CD11c
＋ DC. The incidence of 
labeled DC migration to DLN was expressed as a percent of 
fluorescent cells (C) This result is representative of 3 experiments that 
gave similar results. **p＜0.01 for a comparison with DC alone.
Interestingly, tumors in mice that received DPT-treated DCs 
w e r e  s i g n i f i c a n t l y  s m a l l e r  t h a n  t h o s e  t h a t  r e c e i v e d  B 1 6 - T P -  
DCs. These findings indicate that DPT can enhance immuni-
zation efficacy to protect mice from lethal challenge by the 
tumor.
DPT-treated DCs enhance priming of specific CTL 
activity and production of IFN-γ
DPT-treated DCs induce both increased survival rate and re-
duction of tumor size in mice in comparison to B16-TP-DCs 
challenge alone (Fig. 6). DPT-treated DCs therefore increase 
the antitumor response through enhancement of CTL activity 
and  Th1 immunity.  Thus,  to  determine  their  effect on  host 
T  cell  responses,  IFN-γ production  and  CTL  activity  were 
analyzed.  Lymphocytes  isolated  from  tumor-implanted  mice 
from  different  groups  were  co-cultured  with  mitomycin-in-
activated B16F10 cells for 7 days in the presence of IL-2, after 
which CTL cells were collected. B16F10 melanoma cells were 
used as target cells. CTL activity was determined using a lac-
tate dehydrogenase release assay at effector: target ratios of 
10：1, 25：1, and 50：1. Splenic CTL activity of cells har-
vested  from  DPT-treated  DCs-injected  mice  (50：1  ra-
tio=34.1%±2.07 (p＜0.001)) was greater than in cells from 
mice  injected  with  only  B16-TP-DCs  (50：1  ratio=23.5%± 
1.26 (p＜0.001) (Fig. 6C). To determine whether DPT-treated 
DCs enhance Th1 cytokine production following intratumoral 
treatment, IFN-γ and IL-2 secretion from splenocytes derived 
from tumor-implanted mice were analyzed by ELISA 7 days 
post-injection. Production of IFN-γ and IL-2 from lympho-
cytes derived from mice injected with DPT-treated DCs was 
significantly higher than that from B16-TP-DCs (Fig. 6D and 
E).  Moreover,  DPT-treated  DCs  exhibited  greater  antitumor 
activity in comparison to B16-TP-treated DCs and its admin-
istration  as  increased  expression  of  MHC  class  I  and  II,  as 
well as CD40, a molecule that interacts with T cells to pro-
mote DC maturation, were observed (Fig. 6F). These data in-Deoxypodophyllotoxin Enhances DC-based Vaccine Efficacy
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Figure 6. DPT-DCs enhance anti-tumor therapeutic efficacy. C57BL/6 mice were injected subcutaneously with 1×10
5 B16F10 cells on day 0.
The tumor-implanted C57BL/6 mice were divided into 4 groups (each group containing 10 mice) and injected in situ with DCs alone ( ◆), 
B16-TP-DCs (□), DPT-DCs (○), and HBSS (■), respectively. Injection of 1×10
6 purified DCs/0.2 ml was performed on day 3, 7, and 14. The
length and width of the tumor mass were measured with calipers at 3, 7, 14, and 28 days. Tumor-implanted mice in each group were observed
for survival time (A) Inhibition of tumor growth in melanoma-implanted C57BL/6 mice by therapy group (B) Splenic lymphocyte isolation from
killed tumor-implanted mice (n=5) 5 days after final injection with HBSS, purified DCs, B16-TP-DCs, and DPT-DCs co-cultured with inactivated
B16F10 cells for 7 days in the presence of recombinant murine IL-12 (20 U/ml) and then collected as CTL effector cells and incubated at the
indicated E：T ratio. CTL activity was determined by LDH release assay with a CytoTox 96 non-radioactive cytotoxicity assay kit (C). ELISA
analysis of IFN-g (D) and IL-2 (E) in the supernatants of 2×10
6/ml lymphocytes isolated at 5 days after the last injection and restimulated with 
inactivated B16F10 cells in vitro at a 10：1 ratio. The DCs were cultured under standard conditions for another 24 h in the presence of B16-TP
or 100 nM DPT, harvested, and analyzed by 2-color cytometry (F). Data are representative of 3 independent experiments. Mice were monitored
for tumor growth and survival. (*p＜0.05, **p＜0.01, DPT-DCs vs. HBSS).Deoxypodophyllotoxin Enhances DC-based Vaccine Efficacy
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Figure 6. Continued.Deoxypodophyllotoxin Enhances DC-based Vaccine Efficacy
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dicate that the enhanced antitumor effect of DPT-treated DCs 
may  be  involved in  increasing  the production  of Th1  cyto-
kines  and  CTL  activity.
DISCUSSION
This study demonstrates that DPT elicits a Th1 response by 
promoting  Th1-related  cytokine  production,  including  IL-12 
and IFN-γ, during DC maturation and activation. Moreover, 
DPT-treated DCs enhance priming of specific CTL activity, cy-
tokine production, and the therapeutic efficacy of DC-based 
immunization against an established tumor in vivo. A variety 
of  immunological  strategies have  been  used  to elicit  strong 
antitumor  effects  in  an  attempt  to  reduce  tumors  (8,40,41). 
Among the various DC-based tumor therapies using specific 
genes  with  an  antigen  transfer  system,  DC-based  im-
munotherapy  focuses  on  the  use  of  antigens  for  cytokines, 
chemokines,  co-stimulatory  molecules,  and  MHC  class  I 
(42,43). Recently, many studies reported the efficacy of anti-
tumor immunotherapy using antigen- or gene-specific pulsed 
DCs (44). In addition, we and others have reported that bac-
terial proteins can induce antitumor activity by increasing DC 
maturation  and  CTL  activity  (8,45).
    In  this  study,  we  sought  to  determine  whether  DPT  can 
elicit DC maturation as an effective adjuvant for DC-based tu-
mor  therapy  and  to  evaluate  the  mechanism  involved.  We 
d e m o n s t r a t e d  t h a t  D P T  t r e a t m e n t  o f  D C s  i n d u c e d  t h e  e x -
pression of co-stimulatory molecules and IL-12 production in 
these cells, thereby inducing CD8
＋ T cell proliferation, IL-2 
and  IFN-γ production,  as  well  as  Th1-mediated  immune 
responses. DCs maturation and IL-12 production was medi-
ated by signaling through TLR4-mediated MAPK and NF-κB 
activation. Previous reports suggested that LPS-mediated in-
duction of IL-12 in DCs is mediated by ERK1/2 and p38 (46), 
which has been linked to enhancement of IL-12 by DCs and 
ultimately a Th1 response (47). Our results indicate that DPT 
treatment induces p38 and ERK phosphorylation in DCs, and 
that induction of IL-12 stimulated IL-2 and IFN-γ production, 
and  promoted  a  Th1-type  response.  These results  are con-
sistent with previous reports showing that enhancement of a 
Th1 immune response results in the suppressive effect of tu-
mor-conditioned medium on IL-12 production by DCs (48). 
Recent studies have also demonstrated that in addition to IFN 
regulatory  factor  5  and  NF-κB ,  o t h e r  p a t h w a y s  a r e  c r i t i c a l 
for  IL-12p70  production  (49).
    Generation of a specific CTL response by the immune sys-
tem may provide a therapeutic approach to cancer. Recent 
papers have demonstrated that the cytotoxic T cell response 
can be bypassed by activation of DCs through expression of 
CD40 (50). DCs also function as a temporal bridge in that, 
once activated, they are conditioned to deliver a kill signal 
to  CD8
＋ C T L .  S e v e r a l  r e p o r t s  h a v e  i m p l i c a t e d  D C s  i n  t h i s  
model, suggesting that the activation state of DCs is more im-
portant than the help of CD4
＋ T cells (50). We developed 
an in vivo model of CTL activity against B16F10 melanoma 
to test the specific CTL priming capacity of differentially ma-
tured DCs. B16-TP-DPT-costimulated DCs induced CTL activ-
ity,  whereas  DPT-matured  DCs  significantly  enhanced  anti-
tumor activity when compared to B16-TP-matured DCs. This 
activity is likely mediated through a T cell interaction mole-
cule such as CD40 and MHC molecules on DCs. Generally, 
DCs are the exclusive APC capable of mediating capture of 
Ag from apoptotic cells of tumor for the generation of MHC 
I/peptide  complexes,  interaction  with  CD40  on  DCs  and 
CD40L on T cells, thus allowing for engagement of CD8
＋ T 
cells  activation  (50).  T  cell  interaction  molecules,  including 
CD40, and MHC class I and II, are expressed at higher levels 
o n  D P T - s t i m u l a t e d  D C s ,  a l l o w i n g  i n c r e a s e d  s t i m u l a t i o n  o f  
CTL  precursors  in  vivo.  DPT-stimulated  DCs  can  then  pro-
duce more IL-12 and elicit IFN-γ production from T cells, 
thus  expanding  CTL.
  O u r  r e s u l t s  s h o w  t h a t  D P T - s timulated  DCs  injected  into 
C57BL/6 tumor-implanted mice in situ can significantly inhibit 
tumor growth and prolong survival. Pathologic examination 
showed that significant tumor necrosis was present inside or 
around the tumor mass following administration of DPT-treat-
ed DCs. These data indicate that injection of DPT-treated DCs 
into  tumor-implanted  mice  can  induce  potent  antitumor 
effects.
  In summary, our results demonstrate that effective DCs ma-
turation and activation by DPT can produce several beneficial 
effects  when administered  as tumor  therapy. These  include 
polarization of tumor-reactive T cell responses toward a Th1 
profile, increased survival rate and activation of CTL, and IFN-
γ production, all of which work with the adaptive immune 
response in the polarization process. These findings also pro-
vide  new  insight  into  the  immunopharmacology  of  DPT.
ACKNOWLEDGEMENTS
This  work  was  supported  for  two  years  by  Pusan  National 
University  Research  Grant.Deoxypodophyllotoxin Enhances DC-based Vaccine Efficacy
Jun Sik Lee, et al.
93 IMMUNE NETWORK http://www.ksimm.or.kr Volume 11 Number 1 February 2011
CONFLICTS OF INTEREST
The authors have declared that there is no conflict of interest.
REFERENCES
1. Tobiásová  Z,  Pospísilová  D,  Miller  AM,  Minárik  I, 
Sochorová K, Spísek R, Rob L, Bartůnková J: In vitro as-
sessment  of  dendritic  cells  pulsed  with  apoptotic  tumor 
cells as a vaccine for ovarian cancer patients. Clin Immunol 
122;18-27,  2007
2. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR: 
Induction of a CD8＋ cytotoxic T lymphocyte response by 
cross-priming requires cognate CD4＋ T cell help. J Exp 
Med  186;65-70,  1997
3. Steinman  RM:  The  dendritic  cell  system  and  its  role  in 
immunogenicity.  Annu  Rev  Immunol  9;271-296,  1991
4. Morisaki  T,  Matsumoto  K,  Onishi  H,  Kuroki  H,  Baba  E, 
Tasaki A, Kubo M , Nakam ura M , Inaba S, Y am aguchi K , 
Tanaka M, Katano  M: Dendritic  cell-based combined im-
munotherapy with autologous tumor-pulsed dendritic cell 
vaccine and activated T cells for cancer patients: rationale, 
current progress, and perspectives. Hum Cell 16;175-182, 
2003
5. Rock KL, Clark K. Analysis of the role of MHC class II pre-
sentation in the stimulation of cytotoxic T lymphocytes by 
antigens targeted into the exogenous antigen-MHC class I 
presentation  pathway.  J  Immunol  156;3721-3726,  1996
6. Salio M, Cerundolo V, Lanzavecchia A: Dendritic cell matu-
ration is induced by mycoplasma infection but not by ne-
crotic  cells.  Eur  J  Immunol  30;705-708,  2000
7. Shimizu K, Thomas EK, Giedlin M, Mulé JJ: Enhancement 
of  tumor  lysate-  and  peptide-pulsed  dendritic  cell-based 
vaccines by the addition of foreign helper protein. Cancer 
Res  61;2618-2624,  2001
8. Jeannin  P,  Renno  T,  Goetsch  L,  Miconnet  I,  Aubry  JP, 
Delneste Y, Herbault N, Baussant T, Magistrelli G, Soulas 
C, Romero P, Cerottini JC, Bonnefoy JY: OmpA targets den-
dritic cells, induces their maturation and delivers antigen 
into the MHC class I presentation pathway. Nat Immunol 
1;502-509,  2000
9. Sloan  JM,  Kershaw  MH,  Touloukian  CE,  Lapointe  R, 
Robbins PF, Restifo NP, Hwu P: MHC class I and class II 
presentation of tumor antigen in retrovirally and adenovir-
ally  transduced  dendritic  cells.  Cancer  Gene  Ther  9;946- 
950,  2002
10. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire 
antigen  from  apoptotic  cells and induce  class I-restricted 
CTLs.  Nature  392;86-89,  1998
11. You Z, Hester J, Rollins L, Spagnoli GC, van der Bruggen 
P, Chen SY: A retrogen strategy for presentation of an intra-
cellular  tumor  antigen  as  an  exogenous  antigen  by  den-
d r i t i c  c e l l s  i n d u c e s  p o t e n t  a n t i t u m o r  T  h e l p e r  a n d  C T L  
responses.  Cancer  Res  61;197-205,  2001
12. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD 
Jr.  Peptide-pulsed  dendritic  cells  induce  antigen-specific 
CTL-mediated protective tumor immunity. J Exp Med 183; 
283-287,  1996
13. Huang J, Tatsumi T, Pizzoferrato E, Vujanovic N, Storkus 
WJ:  Nitric  oxide  sensitizes  tumor  cells  to  dendritic  cell- 
mediated apoptosis, uptake, and cross-presentation. Cancer 
Res  65;8461-8470,  2005
14. Liu Y, Bi X, Xu S, Xiang J: Tumor-infiltrating dendritic cell 
subsets  of  progressive  or  regressive  tumors  induce  sup-
pressive or protective immune responses. Cancer Res 65; 
4955-4962,  2005
15. Jarnicki AG, Conroy H, Brereton C, Donnelly G, Toomey 
D, Walsh K, Sweeney C, Leavy O, Fletcher J, Lavelle EC, 
Dunne P, Mills KH: Attenuating regulatory T cell induction 
by TLR agonists through inhibition of p38 MAPK signaling 
in  dendritic  cells  enhances  their  efficacy  as  vaccine  ad-
juvants  and  cancer  immunotherapeutics.  J  Immunol  180; 
3797-3806,  2008
16. Zanoni  I,  Foti  M,  Ricciardi-Castagnoli  P,  Granucci  F: 
TLR-dependent  activation  stimuli  associated  with  Th1  re-
sponses confer NK cell stimulatory capacity to mouse den-
dritic  cells.  J  Immunol  175;286-292,  2005
17. Kane CM, Cervi L, Sun J, McKee AS, Masek KS, Shapira 
S,  Hunter  CA,  Pearce  EJ:  Helminth  antigens  modulate 
TLR-initiated dendritic cell activation. J Immunol 173;7454- 
7461,  2004
18. Krieg  AM:  Therapeutic  potential  of  Toll-like  receptor  9 
activation.  Nat  Rev  Drug  Discov  5;471-484,  2006
19. Chan  CW,  Crafton  E,  Fan  HN,  Flook  J,  Yoshimura  K, 
Skarica M, Brockstedt D, Dubensky TW, Stins MF, Lanier 
L L ,  P a r d o l l  D M ,  H o u s s e a u  F :  I n t e r f e r o n - p r o d u c i n g  k i l l e r  
dendritic cells provide a link between innate and adaptive 
immunity.  Nat  Med  12;207-213,  2006
20. Kapsenberg ML: Dendritic-cell control of pathogen-driven 
T-cell  polarization.  Nat  Rev  Immunol  3;984-993,  2003
21. Lee  JS,  Lee  JC,  Lee  CM,  Jung  ID,  Jeong  YI,  Seong  EY, 
C h u n g  H Y ,  P a r k  Y M :  O u t e r  m e m b r a n e  p r o t e i n  A  o f  
Acinetobacter baumannii induces differentiation of CD4＋ 
T cells toward a Th1 polarizing phenotype through the acti-
vation of dendritic cells. Biochem Pharmacol 74;86-97, 2007
22. Sivori S, Falco M, Della Chiesa M, Carlomagno S, Vitale M, 
Moretta L, Moretta A: CpG and double-stranded RNA trigger 
human NK cells by Toll-like receptors: induction of cyto-
kine release and cytotoxicity against tumors and dendritic 
cells.  Proc  Natl  Acad  Sci  U  S  A  101;10116-10121,  2004
23. Kim Y, Kim SB, You YJ, Ahn BZ: Deoxypodophyllotoxin; 
the cytotoxic and antiangiogenic component from Pulsatilla 
koreana.  Planta  Med  68;271-274,  2002
24. Sudo K, Konno K, Shigeta S, Yokota T: Inhibitory effects 
of  podophyllotoxin  derivatives  on  herpes  simplex  virus 
replication.  Antivir  Chem  Chemother  9;263-267,  1998
25. Jin M, Moon TC, Quan Z, Lee E, Kim YK, Yang JH, Suh 
SJ, Jeong TC, Lee SH, Kim CH, Chang HW: The naturally 
occurring  flavolignan,  deoxypodophyllotoxin,  inhibits  lip-
opolysaccharide-induced  iNOS  expression  through  the 
NF-kappaB activation in RAW264.7 macrophage cells. Biol 
Pharm  Bull  31;1312-1315,  2008
26. Lyons AB: Analysing cell division in vivo and in vitro using 
flow  cytometric  measurement  of  CFSE  dye  dilution.  J Deoxypodophyllotoxin Enhances DC-based Vaccine Efficacy
Jun Sik Lee, et al.
94 IMMUNE NETWORK http://www.ksimm.or.kr Volume 11 Number 1 February 2011
Immunol  Methods  243;147-154,  2000
27. Préville X, Ladant D, Timmerman B, Leclerc C: Eradication 
of  established  tumors  by  vaccination  with  recombinant 
Bordetella pertussis adenylate cyclase carrying the human 
papillomavirus 16 E7 oncoprotein. Cancer Res 65;641-649, 
2005
28. Abe M, Zahorchak AF, Colvin BL, Thomson AW: Migratory 
responses  of  murine  hepatic  myeloid,  lymphoid-related, 
a n d  p l a s m a c y t o i d  d e n d r i t i c  c e l l s  t o  C C  c h e m o k i n e s .  
Transplantation  78;762-765,  2004
29. Mosca  PJ,  Hobeika  AC,  Clay  TM,  Nair  SK,  Thomas  EK, 
Morse  MA,  Lyerly  HK:  A  subset  of  human  mono-
cyte-derived dendritic cells expresses high levels of inter-
leukin-12 in response to combined CD40 ligand and inter-
feron-gamma  treatment.  Blood  96;3499-3504,  2000
30. Langenkamp  A,  Messi  M,  Lanzavecchia  A,  Sallusto  F: 
Kinetics of dendritic cell activation: impact on priming of 
TH1, TH2 and nonpolarized T cells. Nat Immunol 1;311- 
316,  2000
31. Trinchieri  G:  Interleukin-12:  a  proinflammatory  cytokine 
with immunoregulatory functions that bridge innate resist-
ance  and  antigen-specific  adaptive  immunity.  Annu  Rev 
Immunol  13;251-276,  1995
32. Lutz MB, Assmann CU, Girolomoni G, Ricciardi-Castagnoli 
P :  D i f f e r e n t  c y t o k i n e s  r e g u l a t e  a n t i g e n  u p t a k e  a n d  p r e -
sentation of a precursor dendritic cell line. Eur J Immunol 
26;586-594,  1996
33. An H, Yu Y, Zhang M, Xu H, Qi R, Yan X, Liu S, Wang 
W, Guo Z, Guo J, Qin Z, Cao X: Involvement of ERK, p38 
and NF-kappaB signal transduction in regulation of TLR2, 
TLR4  and  TLR9  gene  expression  induced  by  lipopoly-
saccharide in mouse dendritic cells. Immunology 106;38-45, 
2002
34. MacDonald KP, Kuns RD, Rowe V, Morris ES, Banovic T, 
Bofinger H, O'Sullivan B, Markey KA, Don AL, Thomas R, 
H i l l  G R :  E f f e c t o r  a n d  r e g u l a t o r y  T - c e l l  f u n c t i o n  i s  d i f f e r-
entially  regulated  by  RelB  within  antigen-presenting  cells 
during  GVHD.  Blood  109;5049-5057,  2007
35. Sioud M, Fløisand Y: TLR agonists induce the differentiation 
of human bone marrow CD34＋ progenitors into CD11c＋ 
CD80/86＋ DC capable of inducing a Th1-type response. 
Eur  J  Immunol  37;2834-2846,  2007
36. Sweet CR, Conlon J, Golenbock DT, Goguen J, Silverman 
N:  YopJ  targets  TRAF  proteins  to  inhibit  TLR-mediated 
NF-kappaB,  MAPK  and  IRF3  signal  transduction.  Cell 
Microbiol  9;2700-2715,  2007
37. Guiducci  C,  Ghirelli  C,  Marloie-Provost  MA,  Matray  T, 
Coffman RL, Liu YJ, Barrat FJ, Soumelis V: PI3K is critical 
for the nuclear translocation of IRF-7 and type I IFN pro-
duction  by  human  plasmacytoid  predendritic  cells  in  re-
sponse  to  TLR  activation.  J  Exp  Med  205;315-322,  2008
38. Ato M, Stäger S, Engwerda CR, Kaye PM: Defective CCR7 
expression  on  dendritic  cells  contributes  to  the  develop-
ment of visceral leishmaniasis. Nat Immunol 3;1185-1191, 
2002
39. Catusse J, Spinks J, Mattick C, Dyer A, Laing K, Fitzsimons 
C, Smit MJ, Gompels UA: Immunomodulation by herpesvi-
rus  U51A  chemokine  receptor  via  CCL5  and  FOG-2 
down-regulation plus XCR1 and CCR7 mimicry in human 
leukocytes.  Eur  J  Immunol  38;763-777,  2008
40. Movassagh M, Spatz A, Davoust J, Lebecque S, Romero P, 
P i t t e t  M ,  R i m o l d i  D ,  L i én a r d  D ,  G u g e r l i  O ,  F e r r a d i n i  L ,  
Robert C, Avril MF, Zitvogel L, Angevin E: Selective accu-
mulation  of  mature  DC-Lamp＋ dendritic  cells  in  tumor 
sites is associated with efficient T-cell-mediated antitumor 
response and control of metastatic dissemination in mela-
noma.  Cancer  Res  64;2192-2198,  2004
41. Sancho D, Mourão-Sá D, Joffre OP, Schulz O, Rogers NC, 
Pennington DJ, Carlyle JR, Reis e Sousa C: Tumor therapy 
in  mice  via  antigen  targeting  to  a  novel,  DC-restricted 
C-type  lectin.  J  Clin  Invest  118;2098-2110,  2008
42. Melief  CJ:  Cancer  immunotherapy  by  dendritic  cells. 
Immunity  29;372-383,  2008
43. Hatfield P, Merrick AE, West E, O'Donnell D, Selby P, Vile 
R, Melcher AA: Optimization of dendritic cell loading with 
tumor cell lysates for cancer immunotherapy. J Immunother 
31;620-632,  2008
44. Okada N, Saito T, Masunaga Y, Tsukada Y, Nakagawa S, 
M i z u g u c h i  H ,  M o r i  K ,  O k a d a  Y ,  F u j i t a  T ,  H a y a k a w a  T ,  
Mayumi  T,  Yamamoto  A:  Efficient  antigen  gene  trans-
duction using Arg-Gly-Asp fiber-mutant adenovirus vectors 
can potentiate antitumor vaccine efficacy and maturation of 
murine  dendritic  cells.  Cancer  Res  61;7913-7919,  2001
4 5 . L e e  J S ,  K i m  J W ,  C h o i  C H ,  L e e  W K ,  C h u n g  H Y ,  L e e  J C : 
Anti-tumor activity of Acinetobacter baumannii outer mem-
brane  protein  A  on  dendritic  cell-based  immunotherapy 
against  murine  melanoma.  J  Microbiol  46;221-227,  2008
46. Usluoglu N, Pavlovic J, Moelling K, Radziwill G: RIP2 medi-
ates LPS-induced p38 and IkappaBalpha signaling including 
IL-12 p40 expression in human monocyte-derived dendritic 
cells.  Eur  J  Immunol  37;2317-2325,  2007
47. Kelsall BL, Stüber E, Neurath M, Strober W: Interleukin-12 
production by dendritic cells. The role of CD40-CD40L in-
teractions in Th1 T-cell responses. Ann N Y Acad Sci 795; 
116-126,  1996
48. Iwashita Y, Goto S, Tominaga M, Sasaki A, Ohmori N, Goto 
T, Sato S, Ohta M, Kitano S: Dendritic cell immunotherapy 
with  poly  (D,L-2,4-diaminobutyric  acid)-mediated  intratu-
moral delivery of the interleukin-12 gene suppresses tumor 
growth  significantly.  Cancer  Sci  96;303-307,  2005
49. Takaoka  A,  Yanai  H,  Kondo  S,  Duncan  G,  Negishi  H, 
Mizutani T, Kano S, Honda K, Ohba Y, Mak TW, Taniguchi 
T: Integral role of IRF-5 in the gene induction programme 
activated by Toll-like receptors. Nature 434;243-249, 2005
50. Ridge JP, Di Rosa F, Matzinger P: A conditioned dendritic 
cell can be a temporal bridge between a CD4＋ T-helper 
and  a  T-killer  cell.  Nature  393:474-478,  1998